Rashmi Deshmukh
Real-world experience of using ciclosporin-A 0.1% (Ikervis) in the management of ocular surface inflammatory diseases
Deshmukh, Rashmi; Ting, Darren Shu Jeng; Elsahn, Ahmad; Mohammed, Imran; Said, Dalia G; Dua, Harminder Singh
Authors
Darren Shu Jeng Ting
Ahmad Elsahn
Imran Mohammed
Dalia G Said
Professor HARMINDER DUA HARMINDER.DUA@NOTTINGHAM.AC.UK
PROFESSOR OF OPHTHALMOLOGY AND VISUAL SCIENCES
Abstract
Purpose: To report the real-world experience of using topical ciclosporin, Ikervis, in the management of ocular surface inflammatory diseases (OSIDs).
Methods: This was a retrospective study of patients treated with Ikervis for OSIDs at the Queen’s Medical Centre, Nottingham, between 2016 and 2019. Relevant data, including demographics, indications, clinical parameters, outcomes and adverse events, were collected and analysed for patients who had completed at least 6 months follow-up. For analytic purpose, clinical outcome was categorised as ‘successful’ (resolved or stable disease), ‘active disease’ and ‘drug intolerance’.
Results: 463 patients were included; mean age was 51.1±21.6 years, with a 59.0% female predominance. Mean follow-up was 14.6±9.2 months. The most common diagnosis was dry eye disease (DED; 322, 69.5%), followed by allergic eye disease (AED; 53, 11.4%) and ocular mucous membrane pemphigoid/Steven-Johnson syndrome (OMMP/SJS; 38, 8.2%). Successful treatment was achieved in 343 (74.1%) patients, with 44 (9.5%) requiring additional treatment and 76 (16.4%) reporting drug intolerance. The efficacy of Ikervis was highest in DED (264, 82.0%), followed by OMMP/SJS (25, 65.8%) and post-keratoplasty (7, 50.0%; p
Citation
Deshmukh, R., Ting, D. S. J., Elsahn, A., Mohammed, I., Said, D. G., & Dua, H. S. (2022). Real-world experience of using ciclosporin-A 0.1% (Ikervis) in the management of ocular surface inflammatory diseases. British Journal of Ophthalmology, 106(8), 1087-1092. https://doi.org/10.1136/bjophthalmol-2020-317907
Journal Article Type | Article |
---|---|
Acceptance Date | Feb 17, 2021 |
Online Publication Date | Mar 9, 2021 |
Publication Date | 2022-08 |
Deposit Date | Apr 1, 2021 |
Publicly Available Date | Apr 16, 2021 |
Journal | British Journal of Ophthalmology |
Print ISSN | 0007-1161 |
Electronic ISSN | 1468-2079 |
Publisher | BMJ Publishing Group |
Peer Reviewed | Peer Reviewed |
Volume | 106 |
Issue | 8 |
Pages | 1087-1092 |
DOI | https://doi.org/10.1136/bjophthalmol-2020-317907 |
Keywords | Ophthalmology; Sensory Systems; Cellular and Molecular Neuroscience |
Public URL | https://nottingham-repository.worktribe.com/output/5394342 |
Publisher URL | https://bjo.bmj.com/content/early/2021/03/08/bjophthalmol-2020-317907 |
Files
Bjophthalmol-2020-317907.full
(317 Kb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by-nc/4.0/
You might also like
The ‘barcode sign’ seen on optical coherence tomography of extensive corneal vascularization
(2023)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search